Early Translational I Very few laboratories in the State of
California have the capacity to produce stem cells in compliance
with GMP regulations, ("Good Manufacturing Practices"). This
shortage is critical because it leaves the State deficient in
its ability to produce clinical grade stem cells suitable for
use in human clinical trials. The shortage of these laboratories
and resulting absence of cell lines is a major bottleneck in the
advancement of stem cell-based therapies in California.
[REDACTED], is expected to offer GMP manufacturing services in
early 2009. Working in partnership with the [REDACTED] and the
world-famous [REDACTED], [REDACTED] seeks funding under this
project to use pluripotent cells to grow and create California
based banks of clinical grade stem cell lines. These lines will
then be tested for their ability to differentiate into different
types of cells as follows: 1) neurons (for brain injury
treatment) 2) cardiomyocytes (for heart tissue treatment) and 3)
beta cells (for use in the t